Deutsche Bank AG raised its holdings in AtriCure Inc. (NASDAQ:ATRC) by 59.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 117,065 shares of the medical device company’s stock after acquiring an additional 43,461 shares during the quarter. Deutsche Bank AG owned about 0.30% of AtriCure worth $3,579,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. FMR LLC raised its position in shares of AtriCure by 9.0% in the fourth quarter. FMR LLC now owns 5,778,999 shares of the medical device company’s stock valued at $176,837,000 after purchasing an additional 474,738 shares during the period. BlackRock Inc. raised its position in shares of AtriCure by 11.4% in the fourth quarter. BlackRock Inc. now owns 3,075,083 shares of the medical device company’s stock valued at $94,096,000 after purchasing an additional 314,841 shares during the period. Vanguard Group Inc. raised its position in shares of AtriCure by 4.1% in the third quarter. Vanguard Group Inc. now owns 1,588,574 shares of the medical device company’s stock valued at $55,647,000 after purchasing an additional 63,261 shares during the period. Vanguard Group Inc raised its position in shares of AtriCure by 4.1% in the third quarter. Vanguard Group Inc now owns 1,588,574 shares of the medical device company’s stock valued at $55,647,000 after purchasing an additional 63,261 shares during the period. Finally, Millennium Management LLC raised its position in shares of AtriCure by 31.0% in the fourth quarter. Millennium Management LLC now owns 877,574 shares of the medical device company’s stock valued at $26,854,000 after purchasing an additional 207,472 shares during the period. Hedge funds and other institutional investors own 91.61% of the company’s stock.
In other news, SVP Justin J. Noznesky sold 12,569 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $27.64, for a total value of $347,407.16. Following the sale, the senior vice president now owns 104,068 shares in the company, valued at approximately $2,876,439.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO M. Andrew Wade sold 9,850 shares of the business’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $30.00, for a total transaction of $295,500.00. Following the completion of the sale, the chief financial officer now owns 166,824 shares in the company, valued at approximately $5,004,720. The disclosure for this sale can be found here. Insiders sold a total of 37,419 shares of company stock worth $1,092,907 in the last 90 days. 8.00% of the stock is owned by corporate insiders.
AtriCure stock traded down $0.14 on Wednesday, hitting $29.70. The company’s stock had a trading volume of 156,337 shares, compared to its average volume of 236,852. The firm has a market capitalization of $1.15 billion, a PE ratio of -31.60 and a beta of 0.29. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.37 and a quick ratio of 3.69. AtriCure Inc. has a one year low of $23.56 and a one year high of $36.49.
AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Thursday, February 28th. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). AtriCure had a negative net margin of 7.98% and a negative return on equity of 14.35%. The business had revenue of $52.89 million during the quarter, compared to the consensus estimate of $51.62 million. Analysts predict that AtriCure Inc. will post -0.73 earnings per share for the current fiscal year.
ATRC has been the topic of a number of research reports. BTIG Research reaffirmed a “hold” rating on shares of AtriCure in a research report on Tuesday, March 5th. Northland Securities reaffirmed a “buy” rating on shares of AtriCure in a research report on Friday, April 26th. JPMorgan Chase & Co. initiated coverage on shares of AtriCure in a research report on Friday, April 12th. They set an “overweight” rating and a $37.00 target price on the stock. BidaskClub lowered shares of AtriCure from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. Finally, Zacks Investment Research lowered shares of AtriCure from a “buy” rating to a “sell” rating in a research report on Tuesday, March 5th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $35.71.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Sundance Herald and is the sole property of of Sundance Herald. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://sundanceherald.com/2019/05/22/atricure-inc-atrc-stake-increased-by-deutsche-bank-ag.html.
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.
Featured Article: What is a Reverse Stock Split?
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.